Ribavirin for COVID-19
Ribavirin has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292 ,
Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845 ,
Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110 ,
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004 ,
Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015 ,
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase, Molecular Diversity, doi:10.1007/s11030-021-10215-5 ,
In silico evaluation of potential intervention against SARS-CoV-2 RNA-dependent RNA polymerase, Physics and Chemistry of the Earth, Parts A/B/C, doi:10.1016/j.pce.2022.103350 ,
Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316 ,
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279 ,
Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024 ,
Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256 ,
Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736 ,
Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.